



July 08, 2014

The Corporate Relationship Department
BSE Limited,
Floor 25 , P J Towers, Dalal Street
Mumbai - 400 001.
Fax: 022-22722041, 22722061, 22722039, 22723121, 22723719

The Manager - Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
Fax: 022-26598237, 26598238, 26598347, 26598348

Dear Sirs/Madam,

Sub: Clause 36 of the Listing Agreement - Press Release

Please find attached press release on successful completion of US FDA and Mexican COFEPRIS inspection at its API facility at Cuddalore for your perusal.

Kindly take the above on record and acknowledge.

Thanking you,

Yours faithfully,
For Shasun Pharmaceuticals Limited

S. Murali Krishna
Company Secretary

Encl.: Press release

SCGA/F-001/JJ/14

Shasun Pharmaceuticals Limited

(Formerly known as Shasun Chemicals and Drugs Ltd.)
"Batra Centre"

No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai-600 032, India.

Phone: 91-44-4344 6700 / 2220 7500, Fax: 91-44-2235 0278

email : shasun@shasun.com Website : www.shasun.com

TIN No. 33191540153, CST No.39072 / 06.09.76

CIN : L24117TN1976PLC007122



Shasun Pharmaceuticals Limited

3rd & 4th Floor, 'Batra Centre',
28, Sardar Patel Road, Guindy,
Chennai - 600032, Tamil Nadu,
India.

Press release

Successful completion of US FDA and Mexican COFEPRIS inspection

Chennai, 8th July 2014

Shasun Pharmaceuticals Ltd ("Shasun"), a global pharmaceutical organization offering world class capabilities and facilities has successfully completed both US FDA and Mexican COFEPRIS (Mexican Regulatory Authority) inspection at its API facility at Cuddalore Tamil Nadu, India. The USFDA audit was held on second week of June 2014 and the Mexican COFEPRIS audit by APIF was held during the last week of June 2014.

On completion of the inspection the USFDA inspectors concluded that the facility, systems and practices comply with USFDA requirements with minor 483s and on completion of the inspection APIF concluded that Shasun's compliance with current Good Manufacturing Practices (cGMP) are fully met and a formal GMP certificate will be issued by COFEPRIS in due course

About Shasun Pharmaceuticals Limited:

Shasun Pharmaceuticals Ltd, listed on the Bombay Stock Exchange Limited (stock code: 524552) and the National Stock Exchange of India Limited (stock code: SHASUNPHAR) is a leading manufacturer of APIs and formulations, catering to global customers, with world class capabilities and facilities. Shasun offers formulation and generic manufacturing services at its Indian sites together with a contract research and manufacturing services for APIs in India and UK. For more information about Shasun Pharmaceuticals Ltd please visit www.shasun.com.

For further information please contact:

Shasun Pharmaceutical Limited

Mr. S. Hariharan,
Chief Financial Officer
hari@shasun.com
+91 98410 46299

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Shasun Pharmaceuticals Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.